Skip to main
VERU
VERU logo

Veru (VERU) Stock Forecast & Price Target

Veru (VERU) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Veru Inc. is advancing its drug development program, particularly in metabolic diseases and oncology, with promising results from the Phase 2b QUALITY trial for Enobosarm, which has garnered positive topline results and secured a meeting with the FDA to discuss Phase 3 design. The company is expected to achieve profitability by 2029, driven by its focused market approach and successful trial outcomes, positioning it strategically within the micro-cap biopharma niche. While risks related to capital requirements and limited product diversification exist, management's relevant experience and the positive momentum in clinical trials contribute to a cautious yet optimistic outlook on Veru's future performance.

Bears say

Veru Inc. faces significant risks related to changing industry fundamentals, which could adversely affect expected revenues and earnings, particularly in a competitive biopharmaceutical environment. The company's reliance on key revenue-generating markets like the USA, alongside emerging competition and shifting investor sentiment, poses additional challenges to its market positioning. Furthermore, unforeseen developments concerning management practices or financial stability may further complicate the company's valuation outlook, heightening the negative sentiment regarding its stock.

Veru (VERU) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veru and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veru (VERU) Forecast

Analysts have given Veru (VERU) a Buy based on their latest research and market trends.

According to 2 analysts, Veru (VERU) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veru (VERU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.